What Are the Firm Value Implications of SEC-Challenged Shareholder Proposals?
Management Science · 2025-06 · 71 (6) · 4728-4756
DOI: 10.1287/mnsc.2022.01344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Management Science, 2025-06. Verfasst von Maxime Couvert. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
The Securities and Exchange Commission (SEC) permits managers to request the exclusion of shareholder-initiated proposals. I construct a novel data set of excluded and withdrawn proposals from the SEC’s responses to managers’ requests. An examination of announcement returns to withdrawal and exclusion decisions demonstrates that SEC-challenged proposals are value destroying. I find that special interest investors pursuing self-serving agendas and retail investors advocating for one-size-fits-all reforms explain the value-destroying nature of SEC-challenged proposals. On average, the SEC challenge benefits firm value by filtering out these harmful proposals. However, a regression discontinuity design reveals that proposals the SEC refuses to exclude may receive majority shareholder support and destroy firm value. This paper was accepted by Suraj Srinivasan, accounting. Funding: I thank the Swiss Finance Institute for its generous financial support. Supplemental Material: The online appendix and data files are available at https://doi.org/10.1287/mnsc.2022.01344 .
Zitieren
APA
Couvert, M. (2025). What Are the Firm Value Implications of SEC-Challenged Shareholder Proposals?. Management Science, 71(6), 4728-4756. https://doi.org/10.1287/mnsc.2022.01344
Vancouver
Couvert M. What Are the Firm Value Implications of SEC-Challenged Shareholder Proposals?. Management Science. 2025;71(6):4728-4756. doi:10.1287/mnsc.2022.01344
BibTeX
@article{Couvert2025,
author = {Couvert, Maxime},
title = {What Are the Firm Value Implications of SEC-Challenged Shareholder Proposals?},
journal = {Management Science},
year = {2025},
volume = {71},
number = {6},
pages = {4728--4756},
doi = {10.1287/mnsc.2022.01344}
}
EUVIMED